Literature DB >> 842385

Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors.

M Thorup, R Fog.   

Abstract

Eleven male, chronic schizophrenic, hospitalized patients, treated with a constant dose of clozapine (range 200-600 mg daily) as their only neuroleptic medication were studied for a long period of time (minimum 12 weeks). Wide variations in the plasma concentration of clozapine were found in different patients who received the same oral dose, as well as great changes from week to week in the individual patient given a constant dose. The plasma levels of clozapine appeared to have no correlation with either the clinical effect or the side effects. No differences with regard to coagulation factors were found between the patients and the controls.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 842385     DOI: 10.1111/j.1600-0447.1977.tb00148.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  15 in total

Review 1.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 2.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

3.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

4.  Clinical pharmacokinetics of clozapine in chronic schizophrenic patients.

Authors:  Y F Cheng; T Lundberg; U Bondesson; L Lindström; J Gabrielsson
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection.

Authors:  U Bondesson; L H Lindström
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 6.  Clozapine plasma level monitoring: current status.

Authors:  T B Cooper
Journal:  Psychiatr Q       Date:  1996

7.  CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study.

Authors:  C Nordin; B Almé; U Bondesson
Journal:  Psychopharmacology (Berl)       Date:  1995-11       Impact factor: 4.530

Review 8.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

Review 9.  Pharmacokinetics and pharmacodynamics of clozapine.

Authors:  M W Jann; S R Grimsley; E C Gray; W H Chang
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.